Geode Capital Management
CRXT

Geode Capital Management’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Geode Capital Management’s Portfolio CRXT Stock Details CRXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-301,652
Closed -$115K – 5072
2022
Q2 		$115K Buy
301,652
+267,737
+789% +$187K ﹤0.01% 4538
2022
Q1 		$50K Buy
+33,915
New +$43.1K ﹤0.01% 4805

Other funds holding CRXT

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Geode Capital Management's CRXT Position: Q3 2022 in Review

Geode Capital Management sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q3 2022, closing a stake of 301,652 shares — an estimated $115K sold.

Geode Capital Management first reported a position in CRXT in Q1 2022 and held it in 2 quarters. The position peaked at $115K in Q2 2022. 2 funds tracked by Wall St. Rank hold CRXT as of Q3 2022.

  • Geode Capital Management reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Geode Capital Management sold 301,652 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $115K.
  • Geode Capital Management first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • Geode Capital Management's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $115K in Q2 2022.
  • 2 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Geode Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.